Company intelligence / Profile preview

EyeCool Therapeutics

Cambridge, Massachusetts, United Stateseyecooltx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

EyeCool Therapeutics has developed ETX-4143, an investigational cooling device for the treatment of chronic ocular surface pain. In a recent randomized, double-masked pilot study involving 31 patients in Australia, the device demonstrated statistically significant reduction in eye pain severity and immediate as well as lasting relief. The procedure is performed in-office and targets myelinated long ciliary nerves via topical cooling. Additional studies are ongoing to evaluate its effectiveness for other indications such as ocular hypertension.

Therapeutic areas: Ophthalmology
Modalities: Device (specifically, a cooling device for ocular surface application)
Industry: Therapeutic Medical Devices

Partnerships

Catalyst Health Ventures

Beyond the preview

Go deeper on EyeCool Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EyeCool Therapeutics.

Explore the full profile